Your email has been successfully added to our mailing list.

×
-0.00840336134453781 -0.0221848739495798 -0.00302521008403361 -0.0168067226890756 -0.0302521008403361 -0.0105882352941176 -0.0845378151260503 -0.080672268907563
Stock impact report

Biohaven Pharma says acute migraine treatment succeeds in study [Reuters]

Biohaven Ltd. Common Shares (BHVN) 
Last biohaven ltd. common shares earnings: 2/25 04:45 pm Check Earnings Report
US:NYSE Investor Relations: investors.biohavenpharma.com
Company Research Source: Reuters
Biohaven Pharma says acute migraine treatment succeeds in study (Reuters) - Biohaven Pharmaceutical Holding Company Ltd said on Tuesday two doses of its experimental treatment for acute migraine were effective in reducing headaches in a large study. The drug, vazegepant, belongs to a new class of treatments for migraine called CGRP inhibitors. Show less Read more
Impact Snapshot
Event Time:
BHVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
BHVN alerts

from News Quantified
Opt-in for
BHVN alerts

from News Quantified